1. Academic Validation
  2. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors

CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors

  • Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10477-82. doi: 10.1073/pnas.93.19.10477.
D W Schulz 1 R S Mansbach J Sprouse J P Braselton J Collins M Corman A Dunaiskis S Faraci A W Schmidt T Seeger P Seymour F D Tingley 3rd E N Winston Y L Chen J Heym
Affiliations

Affiliation

  • 1 Department of Neuroscience, Pfizer Central Research, Groton, CT 06340, USA.
Abstract

Here we describe the properties of CP-154,526, a potent and selective nonpeptide antagonist of corticotropin (ACTH) releasing factor (CRF) receptors. CP-154,526 binds with high affinity to CRF receptors (Ki < 10 nM) and blocks CRF-stimulated Adenylate Cyclase activity in membranes prepared from rat cortex and pituitary. Systemically administered CP-154,526 antagonizes the stimulatory effects of exogenous CRF on plasma ACTH, locus coeruleus neuronal firing and startle response amplitude. Potential anxiolytic activity of CP-154,526 was revealed in a fearpotentiated startle paradigm. These data are presented in the context of clinical findings, which suggest that CRF is hypersecreted in certain pathological states. We propose that a CRF antagonist such as CP-154,526 could affirm the role of CRF in certain psychiatric diseases and may be of significant value in the treatment of these disorders.

Figures
Products